LifeVantage Corporation's Q2/FY2025 results were boosted by the successful launch of the MindBody GLP-1 system. LFVN revenues jumped by more than 40% on a sequential basis, while free cash flow of $8.7 million represented a new multi-year high. However, elevated commissions and incentive expenses impacted profitability, thus resulting in a rather mediocre Adjusted EBITDA margin of 9.6%.
LifeVantage Corporation (NASDAQ:LFVN ) Q2 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Reed Anderson – Managing Director-ICR Steve Fife – President and Chief Executive Officer Carl Aure – Chief Financial Officer Conference Call Participants Aaron Wukmir – Lake Street Capital Markets Alex Fuhrman – Craig-Hallum Capital Group Doug Lane – Water Tower Research Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to today's conference call to discuss LifeVantage's Second Quarter of Fiscal 2025 Results.
Technology leader brings decades of expertise in innovation, scalability and customer-focused solutions to accelerate LifeVantage's growth and digital transformation Technology leader brings decades of expertise in innovation, scalability and customer-focused solutions to accelerate LifeVantage's growth and digital transformation
New Innovations and Incentives Empower Consultants to Accelerate Business Growth in 2025 New Innovations and Incentives Empower Consultants to Accelerate Business Growth in 2025
The 'Undercovered' Dozen series highlights lesser-covered stocks, offering investment ideas and encouraging discussion among investors. Pacifica Yield highlights Brookfield Infrastructure's subordinated notes with a 32% discount opportunity and a 7.2% yield, backed by a strong balance sheet and diversified assets. Cerence Inc.'s partnership with Nvidia boosts its AI capabilities according to Uttam Dey, but caution is advised due to recent stock surge and potential volatility.
LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs from the likes of Zepbound and Ozempic. The recent launch has exceeded expectations by a wide margin. On Wednesday, the company preannounced stellar Q2/FY2025 results. Preliminary Q2/FY2025 revenues of $67.5 million exceeded consensus expectations by more than 30% and active accounts of approximately 146,000 represented the highest level in almost two years.
SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer, and Carl Aure, Chief Financial Officer, will participate in the 27th Annual ICR Conference to be held January 13-15, 2025 in Orlando, FL.
SALT LAKE CITY, Oct. 29, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its first fiscal quarter ended September 30, 2024.
SALT LAKE CITY, Oct. 29, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.04 per share of common stock, which will be paid December 16, 2024 to all stockholders of record at the close of business on December 2, 2024.
SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its first quarter ended September 30, 2024, after the stock market closes on Tuesday, October 29, 2024. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.